Huber Capital Management LLC cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 36,659 shares of the company’s stock after selling 200 shares during the quarter. Eli Lilly and makes up approximately 2.1% of Huber Capital Management LLC’s holdings, making the stock its 12th biggest holding. Huber Capital Management LLC’s holdings in Eli Lilly and were worth $8,414,000 at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of the company. Atlas Capital Advisors LLC lifted its position in Eli Lilly and by 64.6% during the second quarter. Atlas Capital Advisors LLC now owns 107 shares of the company’s stock valued at $25,000 after purchasing an additional 42 shares during the period. Penserra Capital Management LLC acquired a new position in shares of Eli Lilly and in the 2nd quarter worth approximately $33,000. Financial Insights Inc. purchased a new stake in Eli Lilly and during the 2nd quarter worth approximately $36,000. Altshuler Shaham Ltd purchased a new stake in shares of Eli Lilly and in the 1st quarter valued at approximately $42,000. Finally, Corsicana & Co. purchased a new position in shares of Eli Lilly and in the 2nd quarter valued at $46,000. 81.65% of the stock is currently owned by institutional investors and hedge funds.
Several analysts recently commented on LLY shares. Berenberg Bank upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and raised their price objective for the company from $240.00 to $270.00 in a research note on Monday. Citigroup raised shares of Eli Lilly and from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $210.00 to $265.00 in a report on Wednesday, September 29th. They noted that the move was a valuation call. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $300.00 price objective on shares of Eli Lilly and in a report on Friday, September 24th. Truist began coverage on shares of Eli Lilly and in a report on Tuesday, July 27th. They issued a “buy” rating and a $262.00 price objective for the company. Finally, Cantor Fitzgerald upped their price objective on shares of Eli Lilly and from $245.00 to $300.00 and gave the stock an “overweight” rating in a report on Thursday, June 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $258.22.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Monday, August 2nd. The company reported $1.87 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.89 by ($0.02). The business had revenue of $6.74 billion during the quarter, compared to analysts’ expectations of $6.59 billion. Eli Lilly and had a return on equity of 119.12% and a net margin of 22.71%. Eli Lilly and’s quarterly revenue was up 22.6% compared to the same quarter last year. During the same period last year, the firm posted $1.89 EPS. Analysts anticipate that Eli Lilly and Company will post 7.87 EPS for the current fiscal year.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 236,542 shares of the company’s stock in a transaction dated Tuesday, August 3rd. The shares were sold at an average price of $256.12, for a total value of $60,583,137.04. Following the transaction, the insider now owns 108,537,712 shares of the company’s stock, valued at $27,798,678,797.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 492,615 shares of company stock worth $128,197,709 in the last 90 days. 0.13% of the stock is currently owned by insiders.
About Eli Lilly and
Eli Lilly & Co engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm’s products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity.
Read More: High-Yield Dividend Stocks
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.